Shares of Scancell Holdings plc (LON:SCLP - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 9.58 ($0.13) and traded as low as GBX 9.32 ($0.13). Scancell shares last traded at GBX 9.77 ($0.13), with a volume of 808,910 shares changing hands.
Scancell Stock Up 9.1%
The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The stock has a fifty day moving average price of GBX 10.09 and a two-hundred day moving average price of GBX 9.58. The company has a market cap of £110.49 million, a P/E ratio of -16.36 and a beta of 0.35.
Insider Activity
In other Scancell news, insider Martin Diggle purchased 44,944 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was bought at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,506.34). Corporate insiders own 4.96% of the company's stock.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
